{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:38:28Z","timestamp":1791362308801,"version":"4.3.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CHR-2797 is a novel metalloenzyme inhibitor that is converted into a pharmacologically active acid product (CHR-79888) inside cells. CHR-79888 is a potent inhibitor of a number of intracellular aminopeptidases, including leucine aminopeptidase. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines in vitro and in vivo and shows selectivity for transformed over nontransformed cells. Its antiproliferative effects are at least 300 times more potent than the prototypical aminopeptidase inhibitor, bestatin. However, the mechanism by which inhibition of these enzymes leads to proliferative changes is not understood. Gene expression microarrays were used to profile changes in mRNA expression levels in the human promyelocytic leukemia cell line HL-60 treated with CHR-2797. This analysis showed that CHR-2797 treatment induced a transcriptional response indicative of amino acid depletion, the amino acid deprivation response, which involves up-regulation of amino acid synthetic genes, transporters, and tRNA synthetases. These changes were confirmed in other leukemic cell lines sensitive to the antiproliferative effects of CHR-2797. Furthermore, CHR-2797 treatment inhibited phosphorylation of mTOR substrates and reduced protein synthesis in HL-60 cells, both also indicative of amino acid depletion. Treatment with CHR-2797 led to an increase in the concentration of intracellular small peptides, the substrates of aminopeptidases. It is suggested that aminopeptidase inhibitors, such as CHR-2797 and bestatin, deplete sensitive tumor cells of amino acids by blocking protein recycling, and this generates an antiproliferative effect. CHR-2797 is orally bioavailable and currently undergoing phase II clinical investigation in the treatment of myeloid leukemia. [Cancer Res 2008;68(16):6669\u201379]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-6627","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T00:48:12Z","timestamp":1218588492000},"page":"6669-6679","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells"],"prefix":"10.1158","volume":"68","author":[{"given":"David","family":"Krige","sequence":"first","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"},{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"Needham","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"},{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay J.","family":"Bawden","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"},{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Flores","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Farmer","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.C.","family":"Miles","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stone","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Callaghan","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chandler","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Clark","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kirwin-Jones","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vale\u0301rie","family":"Legris","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Owen","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakor","family":"Patel","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Wood","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Box","sequence":"additional","affiliation":[{"name":"3The Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laber","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Odedra","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Wright","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Michael","family":"Wood","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne A.","family":"Eccles","sequence":"additional","affiliation":[{"name":"3The Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"Bone","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"},{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ayscough","sequence":"additional","affiliation":[{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Drummond","sequence":"additional","affiliation":[{"name":"1Chroma Therapeutics Ltd., Abingdon, United Kingdom;"},{"name":"2British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,8,12]]},"reference":[{"key":"2022061700303101000_B1","doi-asserted-by":"crossref","unstructured":"Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer\u20082002; 2: 657\u201372.","DOI":"10.1038\/nrc884"},{"key":"2022061700303101000_B2","doi-asserted-by":"crossref","unstructured":"Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs\u20082007; 16: 659\u201378.","DOI":"10.1517\/13543784.16.5.659"},{"key":"2022061700303101000_B3","doi-asserted-by":"crossref","unstructured":"Ichinose Y, Genka K, Koike T, et al. Randomised double-blind placebo-controlled trial of bestatin in patients with resected stage 1 squamous cell carcinoma. J Natl Cancer Inst\u20082003; 95: 605\u201310.","DOI":"10.1093\/jnci\/95.8.605"},{"key":"2022061700303101000_B4","unstructured":"Brown PD, Bawden LJ, Miller KM. Use of MMP inhibitors 1999; U.S. Patent, US 5,872,152."},{"key":"2022061700303101000_B5","doi-asserted-by":"crossref","unstructured":"Taylor A. Aminopeptidases: structure and function. FASEB J\u20081993; 7: 290\u20138.","DOI":"10.1096\/fasebj.7.2.8440407"},{"key":"2022061700303101000_B6","doi-asserted-by":"crossref","unstructured":"Albiston AL, Ye S, Chai SY. Membrane bound members of the M1 family: more than aminopeptidases. Protein Pept Lett\u20082004; 11: 491\u2013500.","DOI":"10.2174\/0929866043406643"},{"key":"2022061700303101000_B7","doi-asserted-by":"crossref","unstructured":"Sato Y. Role of aminopeptidase in angiogenesis. Biol Pharm Bull\u20082004; 27: 772\u20136.","DOI":"10.1248\/bpb.27.772"},{"key":"2022061700303101000_B8","doi-asserted-by":"crossref","unstructured":"Saveanu L, Carroll O, Lindo V, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol\u20082005; 6: 689\u201397.","DOI":"10.1038\/ni1208"},{"key":"2022061700303101000_B9","doi-asserted-by":"crossref","unstructured":"Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab\u20082001; 2: 67\u201385.","DOI":"10.2174\/1389200013338748"},{"key":"2022061700303101000_B10","doi-asserted-by":"crossref","unstructured":"Sakuraya M, Tamura J, Itoh K, Kubota K, Naruse T. Aminopeptidase inhibitor ubenimex inhibits the growth of leukaemic cell lines and myeloma cells through its cytotoxicity. J Int Med Res\u20082000; 28: 214\u201321.","DOI":"10.1177\/147323000002800503"},{"key":"2022061700303101000_B11","doi-asserted-by":"crossref","unstructured":"Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumours. Biotherapy\u20081992; 4: 205\u201314.","DOI":"10.1007\/BF02174207"},{"key":"2022061700303101000_B12","unstructured":"Pearson LA, Ayscough AP, Huxley P, Drummond AH. Cytostatic Agents 2002 U.S. Patent, US 6,462,023."},{"key":"2022061700303101000_B13","doi-asserted-by":"crossref","unstructured":"Brown PD. Matrix metalloproteinase Inhibitors. Angiogenesis\u20081998; 1: 142\u201354.","DOI":"10.1023\/A:1018373520193"},{"key":"2022061700303101000_B14","doi-asserted-by":"crossref","unstructured":"Constam DB, Tobler AR, Rensing-Ehl A, et al. Puromycin-sensitive aminopeptidase: sequence analysis, expression and functional characterisation. J Biol Chem\u20081995; 270: 26931\u201339.","DOI":"10.1074\/jbc.270.45.26931"},{"key":"2022061700303101000_B15","doi-asserted-by":"crossref","unstructured":"Fafournoux P, Bruhat A, Jousse C. Amino acid regulation of gene expression. Biochem J\u20082000; 351: 1\u201312.","DOI":"10.1042\/bj3510001"},{"key":"2022061700303101000_B16","doi-asserted-by":"crossref","unstructured":"Kilberg MS, Pan Y-X, Chen H, Leung-Pineda V. Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. Annu Rev Nutr\u20082005; 25: 59\u201385.","DOI":"10.1146\/annurev.nutr.24.012003.132145"},{"key":"2022061700303101000_B17","doi-asserted-by":"crossref","unstructured":"Schwarzer R, Dames S, Tondera D, Klippel A, Kaufmann J. TRB3 is a PI3-kinase dependent indicator for nutrient starvation. Cell Signal\u20082006; 18: 899\u2013909.","DOI":"10.1016\/j.cellsig.2005.08.002"},{"key":"2022061700303101000_B18","doi-asserted-by":"crossref","unstructured":"Watatani Y, Kimura N, Shimizu YI, et al. Amino acid limitation induces expression of ATF5 mRNA at the post-transcriptional level. Life Sci\u20082007; 80: 879\u201385.","DOI":"10.1016\/j.lfs.2006.11.013"},{"key":"2022061700303101000_B19","doi-asserted-by":"crossref","unstructured":"Barbosa-Tessmann IP, Pineda VL, Nick HS, Schuster SM, Kilberg MS. Transcriptional regulation of the human asparagine synthetase gene by carbohydrate availability. Biochem J\u20081999; 339: 151\u20138.","DOI":"10.1042\/bj3390151"},{"key":"2022061700303101000_B20","doi-asserted-by":"crossref","unstructured":"Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA\u20082004; 101: 11269\u201374.","DOI":"10.1073\/pnas.0400541101"},{"key":"2022061700303101000_B21","doi-asserted-by":"crossref","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev\u20082004; 18: 1926\u201345.","DOI":"10.1101\/gad.1212704"},{"key":"2022061700303101000_B22","doi-asserted-by":"crossref","unstructured":"Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J\u20082007; 403: 217\u201334.","DOI":"10.1042\/BJ20070024"},{"key":"2022061700303101000_B23","doi-asserted-by":"crossref","unstructured":"Adams JM, Cory S The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene\u20082007; 26: 1324\u201337.","DOI":"10.1038\/sj.onc.1210220"},{"key":"2022061700303101000_B24","doi-asserted-by":"crossref","unstructured":"Selvakumar P, Lakshmikuttyamma A, Dimmock JR, Sharma RK. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta\u20082006; 1765: 148\u201354.","DOI":"10.1016\/j.bbcan.2005.11.001"},{"key":"2022061700303101000_B25","doi-asserted-by":"crossref","unstructured":"Lee MD, She Y, Soskis MJ, et al. Human mitochondrial peptide deformylase, a new anti-cancer target of actinonin-based antibiotics. J Clin Invest\u20082004; 114: 1107\u201316.","DOI":"10.1172\/JCI200422269"},{"key":"2022061700303101000_B26","doi-asserted-by":"crossref","unstructured":"Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A\u20081998; 95: 3003\u20137.","DOI":"10.1073\/pnas.95.6.3003"},{"key":"2022061700303101000_B27","doi-asserted-by":"crossref","unstructured":"Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia\u20081999; 13: 729\u201334.","DOI":"10.1038\/sj.leu.2401388"},{"key":"2022061700303101000_B28","doi-asserted-by":"crossref","unstructured":"Grujic M, Renko M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett\u20082002; 182: 113\u20139.","DOI":"10.1016\/S0304-3835(02)00086-1"},{"key":"2022061700303101000_B29","doi-asserted-by":"crossref","unstructured":"Jousse C, Deval C, Maurin A-C, et al. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. J Biol Chem\u20082007; 282: 15851\u201361.","DOI":"10.1074\/jbc.M611723200"},{"key":"2022061700303101000_B30","doi-asserted-by":"crossref","unstructured":"Lopez AB, Wang C, Huang CC, et al. A feedback transcriptional mechanism controls the level of the arginine\/lysine transporter cat-1 during amino acid starvation. Biochem J\u20082007; 402: 163\u201373.","DOI":"10.1042\/BJ20060941"},{"key":"2022061700303101000_B31","doi-asserted-by":"crossref","unstructured":"Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem\u20082003; 278: 34864\u201373.","DOI":"10.1074\/jbc.M301107200"},{"key":"2022061700303101000_B32","doi-asserted-by":"crossref","unstructured":"Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signalling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem\u20082006; 281: 39128\u201334.","DOI":"10.1074\/jbc.M610023200"},{"key":"2022061700303101000_B33","doi-asserted-by":"crossref","unstructured":"Jiang H-Y, Jiang L, Wek RC. The eIF2 kinase pathway facilitates differential GADD45a expression in response to environmental stress. J Biol Chem\u20082007; 282: 3755\u201365.","DOI":"10.1074\/jbc.M606461200"},{"key":"2022061700303101000_B34","doi-asserted-by":"crossref","unstructured":"Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetase-related sequence in the eIF-2\u03b1 protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol\u20081995; 15: 4497\u2013506.","DOI":"10.1128\/MCB.15.8.4497"},{"key":"2022061700303101000_B35","doi-asserted-by":"crossref","unstructured":"Harding HP, Novoa I, Zhang Y, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Molecular Cell\u20082000; 6: 1099\u2013108.","DOI":"10.1016\/S1097-2765(00)00108-8"},{"key":"2022061700303101000_B36","doi-asserted-by":"crossref","unstructured":"Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol\u20082007; 8: 519\u201329.","DOI":"10.1038\/nrm2199"},{"key":"2022061700303101000_B37","doi-asserted-by":"crossref","unstructured":"Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two step mechanism. Genes Dev\u20081999; 13: 1422\u201337.","DOI":"10.1101\/gad.13.11.1422"},{"key":"2022061700303101000_B38","doi-asserted-by":"crossref","unstructured":"Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J\u20082003; 372: 555\u201366.","DOI":"10.1042\/bj20021266"},{"key":"2022061700303101000_B39","doi-asserted-by":"crossref","unstructured":"Sala-Rabanal M, Loo DD, Hirayama BA, et al. Molecular interactions between dipeptides, drugs and the human intestinal H+-oligopeptide cotransporter hPEPT1. J Physiol\u20082006; 574: 149\u201366.","DOI":"10.1113\/jphysiol.2006.107904"},{"key":"2022061700303101000_B40","doi-asserted-by":"crossref","unstructured":"Stack CM, Lowther J, Cunningham E, et al. Characterisation of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J Biol Chem\u20082007; 282: 2069\u201380.","DOI":"10.1074\/jbc.M609251200"},{"key":"2022061700303101000_B41","doi-asserted-by":"crossref","unstructured":"Dalal S, Klemba M. Roles for two aminopeptidases in vacuolar haemoglobin catabolism in Plasmodium falciparum. J Biol Chem\u20082007; 282: 35978\u201387.","DOI":"10.1074\/jbc.M703643200"},{"key":"2022061700303101000_B42","doi-asserted-by":"crossref","unstructured":"Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol\u20082004; 4: 762\u201374.","DOI":"10.1038\/nri1457"},{"key":"2022061700303101000_B43","doi-asserted-by":"crossref","unstructured":"Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity\u20082005; 22: 633\u201342.","DOI":"10.1016\/j.immuni.2005.03.013"},{"key":"2022061700303101000_B44","doi-asserted-by":"crossref","unstructured":"Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer\u20082000; 83: 800\u201310.","DOI":"10.1054\/bjoc.2000.1353"},{"key":"2022061700303101000_B45","doi-asserted-by":"crossref","unstructured":"Kokkinakis DM, Brickner AG, Kirkwood JM, et al. Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res\u20082006; 4: 575\u201389.","DOI":"10.1158\/1541-7786.MCR-05-0240"},{"key":"2022061700303101000_B46","doi-asserted-by":"crossref","unstructured":"Park I-S, Kang S-W, Shin Y-J, et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer\u20082003; 89: 907\u201314.","DOI":"10.1038\/sj.bjc.6601181"},{"key":"2022061700303101000_B47","doi-asserted-by":"crossref","unstructured":"Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter (LAT1): characterisation of function and expression in tumor cell lines. Biochim Biophys Acta\u20082001; 1514: 291\u2013302.","DOI":"10.1016\/S0005-2736(01)00384-4"},{"key":"2022061700303101000_B48","unstructured":"Kim SG, Kim HH, Kim HK, et al. Differential expression and functional characterisation of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells. Anticancer Res\u20082006; 26: 1989\u201396."},{"key":"2022061700303101000_B49","doi-asserted-by":"crossref","unstructured":"Komatsu K, Tsuda M, Tanaka Y, et al. SAR studies of brasilicardin A for immunosuppressive and cytotoxic activities. Bioog Med Chem\u20082005; 13: 1507\u201313.","DOI":"10.1016\/j.bmc.2004.12.029"},{"key":"2022061700303101000_B50","doi-asserted-by":"crossref","unstructured":"Usui T, Nagumo Y, Watanabe A, et al. Brasilicardin A, a natural immunosuppressant, targets amino acid transport system L. Chem Biol\u20082006; 13: 1153\u201360.","DOI":"10.1016\/j.chembiol.2006.09.006"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/16\/6669\/2593637\/6669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/16\/6669\/2593637\/6669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:42:15Z","timestamp":1655430135000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/16\/6669\/540839\/CHR-2797-An-Antiproliferative-Aminopeptidase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,12]]},"references-count":50,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2008,8,12]]},"published-print":{"date-parts":[[2008,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-6627","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6497138.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497138","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22373582.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373576.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373576","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373582","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,12]]}}}